A Phase II Trial of Dovitinib in BCG-Unresponsive Urothelial Carcinoma with
FGFR3
Mutations or Overexpression: Hoosier Cancer Research Network Trial HCRN 12-157
A Phase II Trial of Dovitinib in BCG-Unresponsive Urothelial Carcinoma with
FGFR3
Mutations or Overexpression: Hoosier Cancer Research Network Trial HCRN 12-157
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started